<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The role of cyclooxygenase-2 (COX-2), its <z:chebi fb="23" ids="18059">lipid</z:chebi> metabolite <z:chebi fb="0" ids="15551">PGE2</z:chebi>, and EP receptors (EP; 1-4) underlying the proinflammatory mechanistic aspects of Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, nasopharyngeal <z:mp ids='MP_0002038'>carcinoma</z:mp>, <z:e sem="disease" ids="C0302592" disease_type="Neoplastic Process" abbrv="">cervical cancer</z:e>, <z:hpo ids='HP_0012125'>prostate cancer</z:hpo>, <z:hpo ids='HP_0003003'>colon cancer</z:hpo>, and <z:hpo ids='HP_0100726'>Kaposi's sarcoma</z:hpo> (KS) is an active area of investigation </plain></SENT>
<SENT sid="1" pm="."><plain>The tumorigenic potential of COX-2 and <z:chebi fb="0" ids="15551">PGE2</z:chebi> through EP receptors forms the mechanistic context underlying the chemotherapeutic potential of <z:chebi fb="2" ids="35475">nonsteroidal anti-inflammatory drugs</z:chebi> (<z:chebi fb="1" ids="35475">NSAIDs</z:chebi>) </plain></SENT>
<SENT sid="2" pm="."><plain>Although role of the COX-2 is described in several <z:mp ids='MP_0001799'>viral</z:mp> associated <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>, the biological significance of the COX-2/<z:chebi fb="0" ids="15551">PGE2</z:chebi>/EP receptor inflammatory axis is extensively studied only in <z:hpo ids='HP_0100726'>Kaposi's sarcoma</z:hpo>-associated <z:e sem="disease" ids="C0019340" disease_type="Disease or Syndrome" abbrv="">herpes</z:e> virus (KSHV/HHV-8) associated <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> such as KS, a multifocal endothelial cell <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> and primary effusion <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (PEL), a B cell-proliferative disorder </plain></SENT>
<SENT sid="3" pm="."><plain>The purpose of this review is to summarize the salient findings delineating the molecular mechanisms downstream of COX-2 involving <z:chebi fb="0" ids="15551">PGE2</z:chebi> secretion and its autocrine and paracrine interactions with EP receptors (EP1-4), <z:chebi fb="0" ids="15551">PGE2</z:chebi>-EP receptor signaling regulating KSHV pathogenesis and latency </plain></SENT>
<SENT sid="4" pm="."><plain>KSHV <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> induces COX-2, <z:chebi fb="0" ids="15551">PGE2</z:chebi> secretion, and EP receptor activation </plain></SENT>
<SENT sid="5" pm="."><plain>The resulting signal cascades modulate the expression of KSHV latency genes (latency associated nuclear antigen-1 [LANA-1] and <z:mp ids='MP_0001799'>viral</z:mp>-FADD like interferon converting enzyme-like- inhibitory protein [vFLIP]) </plain></SENT>
<SENT sid="6" pm="."><plain>vFLIP was also shown to be crucial for the maintenance of COX-2 activation </plain></SENT>
<SENT sid="7" pm="."><plain>The mutually interdependent interactions between <z:mp ids='MP_0001799'>viral</z:mp> proteins (LANA-1/vFLIP) and COX-2/<z:chebi fb="0" ids="15551">PGE2</z:chebi>/EP receptors was shown to play key roles in the biological mechanisms involved in KS and PEL pathogenesis such as blockage of <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, cell cycle regulation, transformation, proliferation, <z:mpath ids='MPATH_177'>angiogenesis</z:mpath>, <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e>, invasion, and immune-suppression </plain></SENT>
<SENT sid="8" pm="."><plain>Understanding the COX-2/<z:chebi fb="0" ids="15551">PGE2</z:chebi>/EP axis is very important to develop new safer and specific therapeutic modalities for KS and PEL, since in addition to COX-2 being a therapeutic target, EP receptors represent ideal targets for pharmacologic agents as <z:chebi fb="0" ids="15551">PGE2</z:chebi> analogues and their blockers/<z:chebi fb="68" ids="48706">antagonists</z:chebi> possess <z:chebi fb="0" ids="35610">antineoplastic</z:chebi> activity, without the reported gastrointestinal and cardiovascular toxicity observed with few a <z:chebi fb="1" ids="35475">NSAIDs</z:chebi> </plain></SENT>
</text></document>